PDCD1 and breast carcinoma: Accordingly, the growth of a transplantable mammary carcinoma cell line could be retarded by DBI/ACBP inhibition using a monoclonal antibody (mAb), but only if this mAb is combined with another one targeting PDCD1/PD-1 (programmed cell death 1), which is a T cell-relevant immune checkpoint.